The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease

被引:75
作者
Clement, Fiona M. [1 ,2 ,3 ]
Klarenbach, Scott [4 ]
Tonelli, Marcello [4 ]
Johnson, Jeffrey A. [5 ]
Manns, Braden J. [1 ,2 ,3 ]
机构
[1] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[2] Univ Calgary, Dept Med, Calgary, AB, Canada
[3] Univ Calgary, Ctr Hlth & Policy Studies, Calgary, AB, Canada
[4] Univ Alberta, Div Nephrol, Dept Med, Edmonton, AB, Canada
[5] Inst Hlth Econ, Edmonton, AB, Canada
关键词
CLINICALLY IMPORTANT DIFFERENCES; LEFT-VENTRICULAR MASS; EPOETIN-ALPHA; HEMODIALYSIS-PATIENTS; ANEMIA CORRECTION; NORMALIZATION; MAINTENANCE; PREDIALYSIS; FRAMEWORK; TRIAL;
D O I
10.1001/archinternmed.2009.112
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment of anemia in chronic kidney disease (CKD) with erythropoietin-stimulating agents (ESAs) is commonplace. The optimal hemoglobin treatment target has not been established. A clearer understanding of the health-related quality of life (HQOL) impact of hemoglobin target levels is needed. We systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (> 12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data. Methods: We conducted a search to identify all RCTs of ESA therapy in patients with anemia associated with CKD (1966-December 2006). Inclusion criteria were (1) 30 or more participants, (2) anemic adults with CKD, (3) epoetin (alfa and beta) or darbepoetin used, (4) a control arm, and (5) reported HQOL using a validated measure. All available SF-36 data underwent meta-analysis using the weighted mean difference. Results: Of 231 full texts screened, 11 eligible studies were identified. The SF-36 was used in 9 trials. Reporting of these data was generally incomplete. Data from each domain of the SF-36 were summarized. Statistically significant changes were noted in the physical function (weighted mean difference [WMD], 2.9; 95% confidence interval [CI], 1.3 to 4.5), general health (WMD, 2.7; 95% CI, 1.3 to 4.2), social function (WMD, 1.3; 95% CI, -0.8 to 3.4), and mental health (WMD, 0.4; 95% CI, 0.1 to 0.8) domains. None of the changes would be considered clinically significant. Conclusions: Our study suggests that targeting hemoglobin levels in excess of 12.0 g/dL leads to small and not clinically meaningful improvements in HQOL. This, in addition to significant safety concerns, suggests that targeting treatment to hemoglobin levels that are in the range of 9.0 to 12.0 g/dL is preferred.
引用
收藏
页码:1104 / 1112
页数:9
相关论文
共 29 条
[1]  
BAHLMANN J, 1991, CONTRIB NEPHROL, V88, P90
[2]   Sufficiently important difference: Expanding the framework of clinical significance [J].
Barrett, B ;
Brown, D ;
Mundt, M ;
Brown, R .
MEDICAL DECISION MAKING, 2005, 25 (03) :250-261
[3]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[4]   Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes [J].
Collins, AJ ;
Brenner, RM ;
Ofman, JJ ;
Chi, EM ;
Stuccio-White, N ;
Krishnan, M ;
Solid, C ;
Ofsthun, NJ ;
Lazarus, JM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (03) :481-488
[5]   Normalization of hemoglobin level in patients with chronic kidney disease and anemia [J].
Drueke, Tilman B. ;
Locatelli, Francesco ;
Clyne, Naomi ;
Eckardt, Kai-Uwe ;
Macdougall, Iain C. ;
Tsakiris, Dimitrios ;
Burger, Hans-Ulrich ;
Scherhag, Armin .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2071-2084
[6]   Effect of dialysis dose and membrane flux in maintenance hemodialysis. [J].
Eknoyan, G ;
Beck, GJ ;
Cheung, AK ;
Daugirdas, JT ;
Greene, T ;
Kusek, JW ;
Allon, M ;
Bailey, J ;
Delmez, JA ;
Depner, TA ;
Dwyer, JT ;
Levey, AS ;
Levin, NW ;
Milford, E ;
Ornt, DB ;
Rocco, MV ;
Schulman, G ;
Schwab, SJ ;
Teehan, BP ;
Toto, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :2010-2019
[7]   Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy [J].
Foley, RN ;
Parfrey, PS ;
Morgan, J ;
Barré, PE ;
Campbell, P ;
Cartier, P ;
Coyle, D ;
Fine, A ;
Handa, P ;
Kingma, I ;
Lau, CY ;
Levin, A ;
Mendelssohn, D ;
Muirhead, N ;
Murphy, B ;
Plante, RK ;
Posen, G ;
Wells, GA .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1325-1335
[8]   A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients [J].
Furuland, H ;
Linde, T ;
Ahlmén, J ;
Christensson, A ;
Strömbom, U ;
Danielson, BG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (02) :353-361
[9]   Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial [J].
Gouva, C ;
Nikolopoulos, P ;
Ioannidis, JPA ;
Siamopoulos, KC .
KIDNEY INTERNATIONAL, 2004, 66 (02) :753-760
[10]   Quantifying heterogeneity in a meta-analysis [J].
Higgins, JPT ;
Thompson, SG .
STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558